

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of pharmaceutical composition for preventing, or treating, ~~or prophylaxis of~~ arthrosis in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) a substance ~~that modulates~~ having an activity in modulating signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.
2. (Currently Amended) The method pharmaceutical composition of claim 1, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~in-inhibiting~~ production of a cytokine by AILIM-expressing cells.
3. (Currently Amended) The method pharmaceutical composition of claim 2, wherein the cytokine is interferon  $\gamma$  ~~which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.~~
4. (Currently Amended) The method pharmaceutical composition of claim 1, wherein the arthrosis is rheumatoid arthritis.
5. (Currently Amended) The method pharmaceutical composition of claim 1, wherein the arthrosis is osteoarthritis.

6. (Currently Amended) The method pharmaceutical composition of claim 1, wherein the substance is a protein substance.

7. (Currently Amended) The method pharmaceutical composition of claim 6, wherein the protein substance is selected from the group consisting of:

- a) an antibody that ~~which~~ binds to AILIM or a portion thereof;
- b) a polypeptide comprising all the whole or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising all the whole or a portion of an extracellular region of AILIM and all the whole or a portion of a constant region of an immunoglobulin heavy chain; and
- d) a polypeptide that ~~which~~ binds to AILIM.

8. (Currently Amended) The method pharmaceutical composition of claim 1, wherein the substance is a non-protein substance.

9. (Currently Amended) The method pharmaceutical composition of claim 8, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

10. (Currently Amended) A method of pharmaceutical composition ~~for preventing, or treating, or prophylaxis of inflammation in a subject, the method comprising administering the subject an effective amount of a composition comprising~~ (a) a substance that modulates having an activity in modulating signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

11. (Currently Amended) The method pharmaceutical composition of claim 10, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~in-inhibiting~~ production of a cytokine by AILIM-expressing cells.

12. (Currently Amended) The method pharmaceutical composition of claim 11, wherein the cytokine is interferon  $\gamma$  ~~which is a cytokine produced by Th1 type T-cells, or interleukin 4 which is a cytokine produced by Th2 type T-cells.~~

13. (Currently Amended) The method pharmaceutical composition of claim 10, wherein the subject has inflammation is hepatitis.

14. (Currently Amended) The method pharmaceutical composition of claim 10, wherein the substance is a protein ~~substance~~.

15. (Currently Amended) The method pharmaceutical composition of claim 14, wherein the protein ~~substance~~ is selected from the group consisting of:

- a) an antibody ~~that which~~ binds to AILIM or a portion thereof;
- b) a polypeptide comprising all the whole or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising all the whole or a portion of an extracellular region of AILIM and all the whole or a portion of a constant region of an immunoglobulin heavy chain;
- and
- d) a polypeptide ~~that which~~ binds to AILIM.

16. (Currently Amended) The method pharmaceutical composition of claim 10, wherein the substance is a non-protein substance.

17. (Currently Amended) The method pharmaceutical composition of claim 16, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

18. (Currently Amended) A ~~method of pharmaceutical composition~~ for preventing, ~~or~~ treating, ~~or prophylaxis of~~ graft versus host reaction ~~or~~ and immune rejection accompanying graft versus host reaction or transplantation of a tissue or organ ~~in a subject, the method~~ comprising ~~administering to the subject an effective amount of a composition comprising (a) a substance that modulates having an activity in modulating~~ signal transduction mediated by AILIM, and ~~(b) a pharmaceutically acceptable carrier.~~

19. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 18, wherein the substance ~~inhibits has an activity in inhibiting~~ proliferation of AILIM-expressing cells or ~~inhibits inhibiting~~ production of a cytokine by AILIM-expressing cells.

20. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 19, wherein the cytokine is interferon  $\gamma$  ~~which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.~~

21. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 18, wherein the substance is a protein ~~substance~~.

22. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 21, wherein the protein ~~substance~~ is selected from the group consisting of:

- a) an antibody ~~that which~~ binds to AILIM or a portion thereof;
- b) a polypeptide comprising ~~all the whole~~ or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising ~~all the whole~~ or a portion of an extracellular region of AILIM and ~~all the whole~~ or a portion of a constant region ~~of an~~ in immunoglobulin heavy chain; and
- d) a polypeptide ~~that which~~ binds to AILIM.

23. (Currently Amended) The method pharmaceutical composition of claim 18, wherein the substance is a non-protein substance.

24. (Currently Amended) The method pharmaceutical composition of claim 23, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

25. (Currently Amended) A method of pharmaceutical composition for preventing or treating an immune response triggered by a foreign antigen or an autoantigen in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) a substance that modulates having an activity of controlling signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

26. (Currently Amended) The method pharmaceutical composition of claim 25, wherein the immune response comprises is production of an antibody against the foreign antigen or the autoantigen, cell proliferation, or production of a cytokine.

27. (Currently Amended) The method pharmaceutical composition of claim 25, wherein the substance inhibits has an activity in inhibiting proliferation of AILIM-expressing cells or inhibits in inhibiting production of a cytokine by AILIM-expressing cells.

28. (Currently Amended) The method pharmaceutical composition of claim 27, wherein the cytokine is interferon  $\gamma$  which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

29. (Currently Amended) The method pharmaceutical composition of claim 25, wherein the substance is a protein substance.

30. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 29, wherein the protein ~~substance~~ is selected from the group consisting of:

- a) an antibody ~~that which~~ binds to AILIM or a portion thereof;
- b) a polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM and all ~~the whole~~ or a portion of a constant region of an immunoglobulin heavy chain;
- and
- d) a polypeptide ~~that which~~ binds to AILIM.

31. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 25, wherein the substance is a non-protein substance.

32. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 31, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.